ArcticZymes expands dsDNase product portfolio

ArcticZymes AS is pleased to announce the launch of dsDNase Glycerol-free Triton FREE. This launch is a continuing step towards maintaining a completely EU REACH compliant product portfolio after Triton X-100 becomes subject to authorisation in January 2021 and facilitate a smooth transition for our existing dsDNase customers. dsDNase Glycerol-free Triton FREE is available for shipping. You can request a …

Biotec Pharmacon ASA – Notice of Extraordinary General Meeting

Tromsø, 13 December 2019: Biotec Pharmacon (OSE: Biotec) will hold an extraordinary general meeting on Monday 6. January 2020 at 12.30 CET at Hotell Continental, Stortingsgata 24/26, Oslo The primary purpose of the meeting is to elect a new member to the Board of Directors. Please find the notice including agenda for the meeting and appendices attached to this disclosuere. The notice and appendicies will be sent …

ArcticZymes launches M-SAN High Quality

December 10, 2019 ArcticZymes is pleased to announce a new and novel member of the Salt Active Nuclease (SAN) portfolio; M-SAN High Quality. The new SAN enzyme builds on the highly demanded SAN High Quality nuclease serving the bio-manufacturing market segment. While SAN HQ is designed to work in the high salt concentration range, M-SAN HQ has been developed to …

Biotec Pharmacon changes its strategic direction and invites shareholders to an information update presentation

Tromsø, Norway, 2nd December 2019 – Biotec Pharmacon (OSE: Biotec) has decided to focus its future on the enzymes business and holds an investor update presentation on 10th December. Seek a new owner for the wound care – Woulgan® Drive profitability through the enzymes business (ArcticZymes) Sales activities in Animal and Consumer health integrated under ArcticZymes.   Biotec has for …